Bausch Health Companies Inc

Latest Results (07.10.2025):

Bausch Health Companies Inc. reported its second quarter of 2025 with consolidated revenues of $2.53 billion, marking a 5% increase on a reported basis and a 4% growth on an organic basis compared to the same period last year. The company achieved a GAAP Net Income attributable to Bausch Health of $148 million and a GAAP Net Income of $128 million. Additionally, the Consolidated Adjusted EBITDA attributable to Bausch Health reached $842 million, reflecting a 6% rise year-over-year.

Consistent Revenue and EBITDA Growth

Bausch Health achieved its ninth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA, excluding Bausch + Lomb. Reported and organic revenue each grew by 5%, while Adjusted EBITDA saw a robust 10% increase, underscoring the company's strong operational performance across its diverse portfolio.

Debt Repayment Plan Initiated

The company announced its intention to repay approximately $900 million of debt using cash on hand following the quarter-end. This strategic move is aimed at strengthening Bausch Health's financial position and reducing leverage.

Strategic Acquisition of DURECT Corporation

Bausch Health entered into an agreement to acquire DURECT Corporation, pending the satisfaction of all closing conditions. This acquisition will leverage Bausch Health's expertise in hepatology to advance the approval and commercialization of DURECT's primary treatment for alcohol-induced hepatitis.

Strong Segment Performance

The Salix segment led revenue growth with a 12% increase to $627 million, driven primarily by Xifaxan®. Solta Medical also showed impressive growth with revenues up 25% to $128 million. While the Diversified segment experienced a 13% decline, Bausch + Lomb maintained steady growth, reporting revenues of $1.28 billion, up 5% year-over-year.

Full-Year 2025 Guidance Reaffirmed

Bausch Health reaffirmed its full-year 2025 guidance for Revenue, Adjusted EBITDA (non-GAAP), and Adjusted Cash Flow from Operations (non-GAAP), reflecting confidence in continued growth and financial stability for the remainder of the year.